Pharmaceutical Meeting highlights from the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) last week included good news for Anglo-Swedish drug maker AstraZeneca (LSE: ANZ) and Swiss major Novartis (NOVN: VX) but, as reported last Friday, not for GlaxoSmithKline, with the Agency calling for the suspension of its once blockbuster diabetes drug Avandia (rosiglitazone) and a negative take on Merck KGaA's cladribine for multiple sclerosis, which caused the latter's share price to tumble near 10% (The Pharma Letter September 24). 26 September 2010